Daily Stock Analysis, HTBX, Heat Biologics Inc, priceseries

Heat Biologics Inc. Daily Stock Analysis
Stock Information
Open
7.25
Close
7.09
High
7.29
Low
6.94
Previous Close
7.08
Daily Price Gain
0.01
YTD High
7.37
YTD High Date
Jan 19, 2021
YTD Low
5.22
YTD Low Date
Jan 4, 2021
YTD Price Change
1.42
YTD Gain
25.04%
52 Week High
30.10
52 Week High Date
Jul 21, 2020
52 Week Low
1.40
52 Week Low Date
Feb 27, 2020
52 Week Price Change
4.99
52 Week Gain
237.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 11. 2017
37.80
Sep 29. 2017
44.09
14 Trading Days
16.65%
Link
LONG
Jan 4. 2019
7.49
Jan 24. 2019
9.28
13 Trading Days
23.96%
Link
LONG
Dec 27. 2019
3.29
Jan 2. 2020
3.46
3 Trading Days
5.32%
Link
LONG
Jan 6. 2020
3.36
Jan 7. 2020
3.53
1 Trading Days
5.22%
Link
LONG
Feb 28. 2020
2.31
Mar 10. 2020
4.65
7 Trading Days
101.33%
Link
LONG
Apr 20. 2020
4.20
Apr 21. 2020
4.45
1 Trading Days
5.83%
Link
LONG
May 22. 2020
5.88
Jun 2. 2020
6.35
6 Trading Days
8.04%
Link
LONG
Jun 26. 2020
6.16
Jun 29. 2020
6.72
1 Trading Days
9.09%
Link
LONG
Jul 15. 2020
10.22
Jul 27. 2020
16.87
8 Trading Days
65.07%
Link
Company Information
Stock Symbol
HTBX
Exchange
NasdaqCM
Company URL
http://www.heatbio.com
Company Phone
919-240-7133
CEO
Jeff A. Wolf
Headquarters
North Carolina
Business Address
801 CAPITOLA DRIVE, DURHAM, NC 27713
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001476963
About

Heat Biologics, Inc. operates as a clinical-stage biopharmaceutical company, with interest in the development of novel allergenic drugs. The company focuses on the commercialization of ImPact Therapy, a platform technology that offers a novel approach to treat cancer and other infectious diseases, including HIV, HCV and malaria by using live, genetically-modified, and irradiated human cells to activate the immune system against specific defined targets. Heat Biologics was founded on June 10, 2008 by Jeffrey Alan Wolf and is headquartered in Durham, NC.

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.